These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15944517)

  • 1. Metabolic abnormalities and the medical management of calcium oxalate nephrolithiasis.
    Chandhoke PS
    Minerva Urol Nefrol; 2005 Mar; 57(1):9-16. PubMed ID: 15944517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats.
    Bushinsky DA; Asplin JR; Grynpas MD; Evan AP; Parker WR; Alexander KM; Coe FL
    Kidney Int; 2002 Mar; 61(3):975-87. PubMed ID: 11849452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal calcium oxalate crystal growth inhibition in severe calcium oxalate nephrolithiasis.
    Porile JL; Asplin JR; Parks JH; Nakagawa Y; Coe FL
    J Am Soc Nephrol; 1996 Apr; 7(4):602-7. PubMed ID: 8724894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of kidney stone formation: an analysis.
    Khan SR
    World J Urol; 1997; 15(4):236-43. PubMed ID: 9280052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolic disorders and kidney stone].
    Nihon Jinzo Gakkai Shi; 1986 Jul; 28(7):995-1007. PubMed ID: 3795610
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation between sKL and Nrf2 plasma levels and calcium oxalate urolithiasis.
    Aihemaitijiang B; Ruotian L; Qi Y; Mahemuti M
    Int Urol Nephrol; 2023 Jul; 55(7):1671-1676. PubMed ID: 37198517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology and management of calcium stones.
    Park S; Pearle MS
    Urol Clin North Am; 2007 Aug; 34(3):323-34. PubMed ID: 17678983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electron paramagnetic resonance study of iron oxalate in calcium oxalate renal stones.
    Shields H; Sane D; Resnick MI
    Invest Urol; 1979 May; 16(6):428-31. PubMed ID: 221436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrolithiasis and intestinal disease.
    Dobbins JW
    J Clin Gastroenterol; 1985 Feb; 7(1):21-4. PubMed ID: 3980960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Throw no stones: how to prevent calcium oxalate renal stones.
    Eichner ER
    Curr Sports Med Rep; 2010; 9(5):260-1. PubMed ID: 20827088
    [No Abstract]   [Full Text] [Related]  

  • 12. Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid.
    Nakagawa Y; Ahmed M; Hall SL; Deganello S; Coe FL
    J Clin Invest; 1987 Jun; 79(6):1782-7. PubMed ID: 3584470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium oxalate nephrolithiasis: defective oxalate transport.
    Borsatti A
    Kidney Int; 1991 Jun; 39(6):1283-98. PubMed ID: 1895680
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical therapy, calcium oxalate urolithiasis.
    Ruml LA; Pearle MS; Pak CY
    Urol Clin North Am; 1997 Feb; 24(1):117-33. PubMed ID: 9048856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prediction of changes in chemical form of urolithiasis].
    Konstantinova OV; Ianenko ÉK
    Urologiia; 2011; (2):19-23. PubMed ID: 21815453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perturbations of the Gut Microbiome and Metabolome in Children with Calcium Oxalate Kidney Stone Disease.
    Denburg MR; Koepsell K; Lee JJ; Gerber J; Bittinger K; Tasian GE
    J Am Soc Nephrol; 2020 Jun; 31(6):1358-1369. PubMed ID: 32381601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between gut microbiota and short chain fatty acids in the renal calcium oxalate stones disease.
    Liu Y; Jin X; Hong HG; Xiang L; Jiang Q; Ma Y; Chen Z; Cheng L; Jian Z; Wei Z; Ai J; Qi S; Sun Q; Li H; Li Y; Wang K
    FASEB J; 2020 Aug; 34(8):11200-11214. PubMed ID: 32645241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiologic evidence for the role of oxalate in idiopathic nephrolithiasis.
    Curhan GC
    J Endourol; 1999 Nov; 13(9):629-31. PubMed ID: 10608513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium oxalate renal stones.
    Prien EL
    Annu Rev Med; 1975; 26():173-9. PubMed ID: 1096755
    [No Abstract]   [Full Text] [Related]  

  • 20. Nephrolithiasis: a consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals.
    Khan SR; Thamilselvan S
    Mol Urol; 2000; 4(4):305-12. PubMed ID: 11156696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.